Dexamethasone intraocular

Drug Overview

In the evolving field of Ophthalmology, managing inflammation after intraocular surgery is essential for achieving optimal visual outcomes and ensuring patient comfort. Historically, post-operative care required strict patient compliance with complex daily eye drop regimens. Dexamethasone intraocular suspension transforms this protocol. As a powerful agent in the Corticosteroid drug class, this medication is placed directly into the eye by the surgeon, effectively eliminating the burden of at-home drop administration for the patient.

• Generic Name: Dexamethasone intraocular suspension
• US Brand Names: Dexycu
• Route of Administration: Intraocular Injection (placed into the posterior chamber behind the iris)
• FDA Approval Status: FDA Approved

This advanced, Preservative-Free formulation serves as a highly effective Targeted Therapy. By delivering a sustained-release dose precisely at the conclusion of surgery, it controls the inflammatory cascade locally, providing a seamless and comfortable recovery experience.

What Is It and How Does It Work? (Mechanism of Action)

Dexamethasone is a highly potent synthetic glucocorticoid. Its mechanism of action relies on the profound suppression of the immune and inflammatory responses that are naturally triggered by surgical trauma.

When a surgical incision is made, mechanical trauma disrupts cell membranes, releasing phospholipids. Dexamethasone works at the molecular level by entering the cells and binding to glucocorticoid receptors. This binding induces the production of lipocortins, which are specialized inhibitory proteins. Lipocortins directly block the action of the enzyme phospholipase A2. By inhibiting this enzyme, dexamethasone halts the release of arachidonic acid, completely shutting down the biochemical pathway responsible for synthesizing inflammatory mediators like prostaglandins and leukotrienes.

Without these mediators, the eye is protected from aggressive vasodilation, the breakdown of the blood-aqueous barrier, and the influx of white blood cells.

The suspension utilizes a proprietary sustained-release technology. When injected into the fluid-filled eye, it immediately forms a single, cohesive, spherical depot. This depot slowly degrades, releasing a steady, microscopic concentration of dexamethasone to the targeted surgical tissues for up to 30 days, providing uninterrupted inflammatory suppression without the peaks and valleys associated with topical drops.

FDA-Approved Clinical Indications

Primary Indication

The primary, FDA-approved indication for dexamethasone intraocular suspension is the treatment of post-operative inflammation following ocular surgery, most notably after cataract extraction and intraocular lens (IOL) implantation.

Other Approved & Off-Label Uses

While specifically designed for cataract surgery, sustained-release corticosteroids are often considered in complex clinical situations:

• Prevention of Cystoid Macular Edema (CME): Used proactively in patients with a history of diabetic retinopathy or uveitis who are at high risk for macular swelling after surgery.
• Chronic Anterior Uveitis: Occasionally utilized off-label to provide extended relief for patients suffering from persistent, non-infectious anterior segment inflammation.

Primary Ophthalmology Indications:

• Stabilize the Blood-Aqueous Barrier: By stopping prostaglandin release, the drug prevents the leakage of inflammatory proteins into the anterior chamber.
• Preserve Visual Acuity: By suppressing aggressive inflammation, the medication reduces the risk of post-operative macular edema, protecting central vision.
• Enhance Patient Compliance: Completely removing the need for tapering topical steroid schedules directly prevents vision-threatening complications caused by missed doses.

Dosage and Administration Protocols

This medication is uniquely administered by an ophthalmic surgeon during an active operative procedure. It is not prescribed for home use.

Specific Instructions for Administration

• Preparation: The suspension is prepared using a specialized administration kit. The surgeon carefully primes the syringe to deliver exactly 0.005 mL of the suspension.
• Surgical Placement: The medication is injected directly into the posterior chamber of the eye (behind the iris) immediately after the intraocular lens has been securely implanted.
• Pediatric Populations: The safety and effectiveness of this specific intraocular depot have not been established in pediatric patients under the age of 18.

Dosage must be individualized by a qualified healthcare professional.

Clinical Efficacy and Research Results

Clinical research spanning 2020-2026 strongly supports the transition toward “dropless” cataract surgery using intraocular Corticosteroid therapy. In large-scale clinical trials and real-world observational studies, patients receiving dexamethasone intraocular suspension demonstrated excellent inflammatory control without needing supplemental topical steroid drops.

Recent data shows that over 60% of treated patients achieve an anterior chamber cell count of zero (complete resolution of cellular inflammation) by post-operative day 8. By day 30, patients maintain steady visual stabilization. Optical Coherence Tomography (OCT) data reveals that these patients maintain highly stable Central Retinal Thickness (CRT) measurements, indicating successful prevention of post-operative macular edema. Furthermore, the mean change in Best Corrected Visual Acuity (BCVA) reliably meets targeted refractive goals quickly, bypassing the visual fluctuations often caused by irregular topical drop usage.

Safety Profile and Side Effects

Black Box Warning: There is NO BLACK BOX WARNING for dexamethasone intraocular suspension, but standard rigorous warnings for intraocular corticosteroids must be observed.

Common Side Effects (>10%)

• Increased Intraocular Pressure (IOP): Steroid-induced IOP spikes are the most common anticipated side effect, occurring in roughly 15% of patients as the drug alters outflow resistance in the trabecular meshwork.
• Anterior Chamber Inflammation: Mild, transient rebound inflammation may occur as the drug depot fully dissolves.
• Corneal Edema: Temporary swelling of the cornea immediately following the surgical procedure itself.

Serious Adverse Events

• Endophthalmitis: A severe, vision-threatening bacterial or fungal infection inside the eye, representing a risk with any intraocular injection or surgery.
• Secondary Glaucoma: Prolonged elevation of IOP that can lead to permanent optic nerve damage if undetected.
• Corneal Melting: Extremely rare, but possible if the patient suffers from severe pre-existing surface disease.

Management Strategies

Surgeons must strictly adhere to sterile administration techniques in the operating room. Post-operatively, measuring the patient’s IOP at the 1-day, 1-week, and 1-month marks is mandatory. If an IOP spike occurs, it is generally highly responsive to standard topical IOP-lowering drops until the steroid depot resolves.

Research Areas

Direct Clinical Connections

Active clinical trials (2020-2026) are highly focused on evaluating the localized impact of sustained-release dexamethasone on corneal endothelial cell density. Because the drug depot rests near the ciliary body and the posterior aspect of the iris, researchers are confirming that continuous local steroid exposure does not accelerate the natural loss of these critical pump cells that maintain corneal clarity.

Generalization and Novel Delivery

The clinical success of this depot has rapidly accelerated the development of next-generation Novel Delivery Systems. The pharmaceutical industry is advancing the concept of completely “dropless” surgery by engineering biodegradable implants that simultaneously release both a Corticosteroid and a non-steroidal anti-inflammatory drug (NSAID).

Severe Disease & Surgical Integration

In patients with complex ocular histories, such as those with chronic uveitis undergoing cataract removal, this medication is being heavily studied as a primary defense against explosive post-operative inflammatory flares. Its use aims to prevent severe structural damage and iris synechiae (adhesions).

Disclaimer: Information in this section regarding the development of biodegradable implants releasing both steroids and NSAIDs and the localized impact on corneal endothelial cell density is considered investigational until a definitive clinical evidence is established. While these concepts are at the forefront of Ophthalmology research in 2026, they are not applicable to practical clinical scenarios.

Patient Management and Clinical Protocols

Pre-treatment Assessment

Because this drug is administered during surgery, the pre-operative workup must be comprehensive:

• Baseline Diagnostics: Baseline Visual Acuity, careful Tonometry (IOP measurement) to identify pre-existing glaucoma risks, and a detailed Slit-lamp exam.
• Ocular Imaging: Macular OCT to establish baseline retinal thickness and rule out underlying macular pathology.
• Screening: A thorough history to identify “steroid responders” (patients who have experienced dangerous eye pressure spikes from steroids previously) and screening for active viral infections like herpes simplex keratitis.

Monitoring and Precautions

• Vigilance: Patients require close clinical monitoring for sudden spikes in IOP, which typically peak between 1 and 2 weeks post-operatively.
• Lifestyle: Patients must follow standard post-cataract surgery protocols, including wearing a protective eye shield while sleeping and using strict UV protection outdoors.

Do’s and Don’ts for Ocular Health

• DO attend all scheduled post-operative appointments so your eye doctor can accurately measure your intraocular pressure.
• DO contact your surgeon immediately if you experience sudden, severe eye pain or a rapid decrease in vision.
• DON’T rub or press on your operated eye under any circumstances.
• DON’T start any other eye drops without explicit instructions from your ophthalmologist, as the injected medication is already actively working inside your eye.

Legal Disclaimer

This medical information is intended for educational purposes only and does not substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified Ophthalmologist regarding surgical procedures, post-operative care, or specific medication regimens. Never disregard professional medical advice or delay seeking care due to information read in this guide. In the event of a medical emergency, contact your physician or local emergency services immediately.